A Multiple Dose Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of ABT-652 Administered Once Daily in Subjects With an Excessive Daytime Sleepiness Disorder.
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2011
At a glance
- Drugs ABT 652 (Primary)
- Indications Hypersomnia; Narcolepsy
- Focus Adverse reactions
- 01 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Apr 2011 Planned End Date changed from 1 Mar 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.
- 24 Jan 2011 Planned End Date changed 1 Dec 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.